Mariana Brandao

Today on #WorldCancerDay we're proud to support our 13K members worldwide as they work on the fundamental research that leads to treatment breakthroughs. #UnitedbyUnique

04.02.2025 09:26 — 👍 27    🔁 8    💬 0    📌 2

What's the Land of Tomorrow of #IO in #NSCLC?
At #ESMOImmune2024 I had the honor to discuss the data on
🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high
🔴 Inupadenant +carbo/pem after IO failure
🔴 Effectiveness & immunophenotype in orphan genomic alterations
@oncoalert.bsky.social #lcsm

13.12.2024 13:39 — 👍 5    🔁 2    💬 0    📌 0

Exciting data at #ESMOImmumo2024 showed by George Coukos on adoptive immune cell therapies:
🔵 Nb of reactive antitumor TILs that are injected correlate with response
🔵 How to improve #TIL treatments in pts with #melanoma
@oncoalert.bsky.social

13.12.2024 10:06 — 👍 5    🔁 1    💬 0    📌 0

How to counteract the immunosuppressive action of #adenosine in #TNBC?
@laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪
@oncoalert.bsky.social #ESMOImmuno2024

13.12.2024 08:35 — 👍 8    🔁 1    💬 0    📌 0

When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!

12.12.2024 14:57 — 👍 5    🔁 2    💬 0    📌 0

Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!

12.12.2024 14:41 — 👍 4    🔁 1    💬 0    📌 0

🧑‍⚕️ Calling #YoungOncologists - Have an idea for a trial or study? The annual #MCCRWorkshop now open for applications!

🗓️ Deadline 31 Jan 2025

@mcrcnews.bsky.social

🔗 ow.ly/2KEB50UohRW

12.12.2024 10:34 — 👍 2    🔁 4    💬 0    📌 0

Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC.

clinicaltrials.gov/study/NCT064...

#bcsm

03.12.2024 10:42 — 👍 7    🔁 5    💬 1    📌 0

Opinion | Her medical file read 'death imminent.' His treatment plan changed cancer forever. | Opinion — USA TODAY Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully used it to save a life.

💥40 years ago today a 33 y/o dying of #metastatic #melanoma got #LAK & #IL-2 & all #cancer went away! Dr. S.A. #Rosenberg (SAR) had the #immune system #cure a patient/I was in SAR’s lab 85-90/incredible era & energy/Great story in @usatoday.com apple.news/AIcm-M7cDQ-O... @sitcancer.bsky.social

30.11.2024 01:32 — 👍 50    🔁 10    💬 1    📌 2

Congratulations @mattiarediti.bsky.social & Christos Sotiriou for this extraordinary work on HER2+ breast cancer!! 💪👏👏

29.11.2024 19:46 — 👍 1    🔁 0    💬 0    📌 0

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR  1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002

Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social

academic.oup.com/jnci/advance...

29.11.2024 14:16 — 👍 27    🔁 15    💬 0    📌 1

Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Introduction: Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, despite advances in immune checkpoint inhibitors and targeted therapies. Antibody–drug c...

⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social

mdpi.com/3031120

29.11.2024 15:15 — 👍 6    🔁 3    💬 0    📌 0

Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social

29.11.2024 16:00 — 👍 12    🔁 3    💬 0    📌 0

🧑‍🔬🏛️👩‍⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky

#StarterPack 1 is already full 🙌, so starting a another one.

Let's continue growing!
- Pack 1️⃣: go.bsky.app/PRdmHCP
- Pack 2️⃣: go.bsky.app/93eqJbs

25.11.2024 18:18 — 👍 50    🔁 17    💬 20    📌 4

ESMO Virtual Journal Club: December 2024 This ESMO Webinar Series is available to all ESMO Members

Don't miss the next #ESMO Virtual Journal Club on Wed 4/Dec🔎📃 we'll discuss:
#LAURA trial: Osi after CRT in #NSCLC 🫁
#RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer

🚨Don't forget to register! 👇
@oncoalert.bsky.social

25.11.2024 17:04 — 👍 5    🔁 2    💬 0    📌 0

18th edition of the Belgian Symposium on the Integration of Molecular Biology -
Friday 29/11 and Saturday 30/11/2024

Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network

www.bordet.be/fr/18th-edit...

13.11.2024 11:58 — 👍 2    🔁 2    💬 0    📌 0

Institut Jules Bordet (part of the) medical oncology team dinner 🤗

@mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!

23.11.2024 15:22 — 👍 4    🔁 2    💬 0    📌 0